Breakthrough medicines during the COVID-19 pandemic era

Eswara Naga Hanuma Kumar Ghali; Vijian Dhevan; Shravan K Narmala; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu

doi:10.4155/fdd-2022-0002

Breakthrough medicines during the COVID-19 pandemic era

Future Drug Discov. 2022 Jan;4(1):FDD69. doi: 10.4155/fdd-2022-0002. Epub 2022 Feb 8.

Authors

Eswara Naga Hanuma Kumar Ghali^{1

2}, Vijian Dhevan³, Shravan K Narmala⁴, Meena Jaggi^{1

2}, Subhash C Chauhan^{1

2}, Murali M Yallapu^{1

2}

Affiliations

¹ Department of Immunology & Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
² South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
³ Department of Surgery, University of Texas Rio Grande Valley, Harlingen, TX 78550, USA.
⁴ DHR Health Hematology Oncology Institute, DHR Health, Edinburg, TX 78539, USA.

No abstract available

Keywords: SARS-CoV-2; antivirals; biopharmaceutics; chemotherapy; food and drug administration; medicine; natural products; oncology; oral drugs; vaccines.

Publication types

Editorial

Publication types

Grants and funding